Skip to main content
. Author manuscript; available in PMC: 2018 Jan 5.
Published in final edited form as: Int J Cancer. 2016 May 4;139(4):836–840. doi: 10.1002/ijc.30100

Figure 1. ZMYM2-FGFR1 driven AML development in NSG mice engrafted with transduced human CD34+ progenitor cells.

Figure 1

a) Enlarged liver and spleen (arrows) is seen in a representative mouse with ZMYM2-FGFR1 AML. b) Survival accumulation was determined using Kaplan-Meier analysis and log-rank (Mantel-Cox) tests (p < 0.04) for mice with ZMYM-FGFR1 AML (n=4) compared with mice engrafted with empty vector transfected CD34+ cells (n=4). c) Flow cytometry analysis with human-specific antibodies shows a myeloid progenitor immunophenotype (CD45+CD13+FLT3+) in bone marrow (BM), spleen (SP) and liver cells.